323 articles with Orexo AB
Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced that Rohan Dixit of Lief Therapeutics was chosen as the winner of the Lyfebulb and Orexo Innovation Challenge: Solutions for Substance Use Disorders. Lief T
- Prior to the Annual General Meeting (AGM) in 2021, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the number of votes in the company as of September 30, 2020 . The Nomination Committee, comprises: Christian Salling , Novo Holdings A/S, also Chairman of the Nomination Committee
Orexo AB, invites investors, analysts, and media to attend a teleconference on Thursday October 1, at 3 pm CET.
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the District of New Jersey with docket number 3:20-cv-12588, against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Indu
Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders
The Challenge recognizes Patient Entrepreneurs with solutions that aid successful, long-term recovery from alcohol and opioid use disorders [01-September-2020] UPPSALA, Sweden and NEW YORK , Sept. 1, 2020 /PRNewswire/ -- Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, an
Orexo AB, announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical Industries Limited.
US launch of the scientifically proven digital therapies deprexis® July 1 and forthcoming launch of vorvida® July 20
FDA's "Enforcement Policy" and Orexo's strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies
Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal
Orexo AB, announces positive results from its human pharmacokinetic study of OX125.
Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced that the Lyfebulb-Orexo Innovation Challenge: Digital Therapeutics for Substance Use Disorder is now accepti
The number of shares and votes in Orexo AB has changed as a result of the cancellation of 842,971 class C shares, which was resolved at the Annual General Meeting held on April 16, 2020.
On 19 May 2020, Orexo AB held an extraordinary general meeting. The extraordinary general meeting passed the following resolutions.
Orexo and Lyfebulb Partner During Unprecedented Times to Help Those Struggling With Alcohol and Opioid Use Disorders
Orexo, a Swedih pharmaceutical company focused on improved pharmaceuticals and digital therapies, announced that it will partner with Lyfebulb, a patient empowerment platform, to work with substance abuse patients to identify unmet needs made more acute by the pandemic,
Orexo's partner, Gesynta Pharma, announces positive phase I results for OX-MPI.
Orexo Acquires Exclusive US Rights to Commercialize deprexis®, A World-leading Digital Therapy to Help Patients Manage the Symptoms of Depression
Orexo AB announces it has acquired the exclusive US rights to GAIA AG's deprexis®, a digital therapy to help patients manage their symptoms of depression and one of the most researched digital therapies in the world.
US Pharma (Zubsolv® US) net revenues of SEK 163.9 m (161.7), up 1.3 percent in SEK and -4.0 percent in local currency. HQ & Pipeline net revenues of SEK 11.1 m (12.6).
The annual general meeting in Orexo AB on 16 April 2020 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be eight with no deputy board members.
The shareholders in Orexo AB, reg. no. 556500-0600, registered office Uppsala, are summoned to the extraordinary general meeting, to be held on Tuesday 19 May 2020, at 11.00 am in Orexo's facilities at Rapsgatan 7E in Uppsala, Sweden.
Orexo AB announces the appointment of James Noble as Chairman of the Board.
The board of directors of Orexo AB has resolved to withdraw the previously communicated proposals to the annual general meeting 2020 concerning the implementation of a new performance-based long-term incentive program for senior executives and key employees within the Orexo group as well as the implementation of a new performance-based long-term incentive program for certain Global Management Team employees and US Leadership Team employees within the Orexo group.